Other languages InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
1.43 ^USD	+14.40%		+15.32%	-12.27%

05-08	InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Transcript : InflaRx N.V. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations	02-22
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904	01-04
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	11-06
Top Premarket Gainers	11-03
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01
Top Premarket Gainers	23-09-21
InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose Phase I Study with C5aR Inhibitor INF904	23-09-11
InflaRx Says Regulatory Review in Europe of Marketing Application for COVID-19 Drug Candidate Underway	23-08-30
Inflarx N.V.'S Marketing Authorization Application for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency	23-08-30
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Top Premarket Gainers	23-08-08
Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023	23-06-28
InflaRX Commercially Launches Gohibic to Treat Seriously Ill COVID-19 Patients in US	23-06-21
InflaRx N.V. Announces Commercial Launch of Gohibic (Vilobelimab) in the U.S. for the Treatment of Critically Ill Covid-19 Patients	23-06-21
WuXi Biologics to Partner with Germany's InflaRx for Manufacture of COVID-19 Treatment	23-05-17
Hong Kong Stocks Slump; Wuxi Bio Drops 4%	23-05-17
InflaRx, WuXi Biologics Sign Manufacturing Deal for COVID-19 Drug	23-05-16
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 Patients	23-05-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages InflaRx N.V.

Equities

IFRX

NL0012661870

Other languages

Filters